Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAP2 | P11137 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976253 | 0.87 | GPR17 (0.48) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31219205 | 0.80 | MAP2 (0.66) | KDM4EALDH1A1SIRT1MAP2 | |
| SCHEMBL13176265 | 0.77 | RXFP1 (0.48) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3871487 | 0.76 | SIRT1 (0.43) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31156425 | 0.75 | MAP2 (0.62) | KDM4EALDH1A1GAASMN1; SMN2MAP2 | |
| SCHEMBL2928362 | 0.75 | RXFP1 (0.40) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16709352 | 0.75 | SIRT1 (0.50) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2351131 | 0.74 | MAPT (0.44) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2347629 | 0.74 | TUBB4A (0.52) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2349425 | 0.74 | CYP1A2 (0.45) | RXFP1PRNPCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633739-A1 | COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | Flare Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024149239-A1 | HETEROAROMATIC CYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024129715-A1 | COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| EP-2104675-B1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | MEDICINES CO LEIPZIG GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2008077631-A1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | BCL6, BCL3, BCL6B | RXFP1 4122/4885PRNP 4521/4885CYP1A2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.